Synageva BioPharma Corp Upgraded to “Outperform” by Wedbush (GEVA)
Synageva BioPharma Corp (NASDAQ:GEVA) was upgraded by equities researchers at Wedbush from a “neutral” rating to an “outperform” rating in a research report issued on Tuesday, TheFlyOnTheWall.com reports. The firm currently has a $93.00 target price on the stock. Wedbush’s price target would suggest a potential upside of 21.35% from the company’s current price. The analysts noted that the move was a valuation call.
Synageva BioPharma Corp (NASDAQ:GEVA) opened at 76.64 on Tuesday. Synageva BioPharma Corp has a one year low of $38.58 and a one year high of $119.42. The stock’s 50-day moving average is $95.82 and its 200-day moving average is $74.77. The company’s market cap is $2.370 billion.
Synageva BioPharma Corp (NASDAQ:GEVA) last released its earnings data on Monday, March 3rd. The company reported ($1.00) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($1.02) by $0.02. The company had revenue of $3.47 million for the quarter, compared to the consensus estimate of $4.88 million. During the same quarter in the prior year, the company posted ($0.62) earnings per share. On average, analysts predict that Synageva BioPharma Corp will post $-5.94 earnings per share for the current fiscal year.
In other Synageva BioPharma Corp news, CMO Anthony Quinn unloaded 20,000 shares of Synageva BioPharma Corp stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $83.53, for a total value of $1,670,600.00. Following the completion of the sale, the chief marketing officer now directly owns 15,524 shares of the company’s stock, valued at approximately $1,296,720. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
GEVA has been the subject of a number of other recent research reports. Analysts at Morgan Stanley reiterated an “overweight” rating on shares of Synageva BioPharma Corp in a research note on Tuesday, April 1st. They now have a $118.00 price target on the stock. Separately, analysts at EVA Dimensions downgraded shares of Synageva BioPharma Corp from a “buy” rating to a “sell” rating in a research note on Friday, March 14th. Finally, analysts at Janney Montgomery Scott reiterated a “fair value” rating on shares of Synageva BioPharma Corp in a research note on Tuesday, March 4th. They now have a $107.00 price target on the stock, up previously from $52.00. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. Synageva BioPharma Corp currently has a consensus rating of “Buy” and an average price target of $110.13.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.